{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:36:44Z","timestamp":1771857404202,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejca.2021.07.028","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T12:12:46Z","timestamp":1629893566000},"page":"149-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases"],"prefix":"10.1016","volume":"156","author":[{"given":"Marie-Luise","family":"Hilbers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1071-7956","authenticated-orcid":false,"given":"Peter","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-8467","authenticated-orcid":false,"given":"Prachi","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant A.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kudura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-1746","authenticated-orcid":false,"given":"Camille L.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell P.","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2940-006X","authenticated-orcid":false,"given":"Phil F.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejca.2021.07.028_bib1","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2021.07.028_bib2","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","article-title":"Evolving treatment options for melanoma brain metastases","volume":"16","author":"Ajithkumar","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.028_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CCO.0000000000000270","article-title":"Treatment of melanoma brain metastases","volume":"28","author":"Goldinger","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.07.028_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2021.07.028_bib5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.25643","article-title":"Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.028_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.028_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CMR.0000000000000029","article-title":"The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival","volume":"24","author":"Vecchio","year":"2014","journal-title":"Melanoma Res"},{"issue":"25","key":"10.1016\/j.ejca.2021.07.028_bib8","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.028_bib9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of Cutaneous melanoma","volume":"161","author":"Network","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.028_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.028_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.07.028_bib12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.07.028_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.028_bib14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in\u00a0patients with BRAF(V600) mutation-positive melanoma with\u00a0symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.028_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.028_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/CMR.0000000000000359","article-title":"Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland","volume":"27","author":"Mangana","year":"2017","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.028_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.028_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.028_bib19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2021.07.028_bib20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.028_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2018.12.023","article-title":"Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases","volume":"110","author":"Rauschenberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.028_bib22","article-title":"First-line\u00a0BRAF\/MEK inhibitors versus anti-PD-1 monotherapy in BRAF","author":"van Breeschoten","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.028_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000333","article-title":"Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG\u2217 study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.028_bib24","first-page":"S672","article-title":"Progression of BRAF mutant CNS metastases are associated with a transcriptional network bearing similarities with the innate PD-1 resistant signature (IPRES)","volume":"31","author":"Lau","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.028_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"7547","key":"10.1016\/j.ejca.2021.07.028_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejca.2021.07.028_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ccell.2015.03.015","article-title":"Radiotherapy complements immune checkpoint blockade","volume":"27","author":"Ngiow","year":"2015","journal-title":"Cancer Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100486X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100486X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:26Z","timestamp":1760733206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100486X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"alternative-id":["S095980492100486X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}